.
MergerLinks Header Logo

Announced

Completed

Pivotal bioVenture Partners led a $145m Series B financing round in Rallybio.

Financials

Edit Data
Transaction Value£119m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pharmaceuticals

Venture Capital

Friendly

United States

biopharmaceuticals

Single Bidder

Acquisition

Completed

Private

Private Equity

Minority

Domestic

Synopsis

Edit

Pivotal bioVenture Partners led a $145m Series B financing round in Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The financing round saw investments from Viking Global Investors, TPG’s The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management, Solasta Ventures, Fairview Capital, and Mitsui & Co, 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations. “The Rallybio team is highly motivated to bring our innovative product candidates to patients suffering from devastating rare disorders. With ambitious plans to progress our current pipeline, expand our portfolio, and grow our team of rare disease experts, we appreciate the profound support of our knowledgeable and esteemed investors,” Martin Mackay, Rallybio Chairman and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US